OPXA Share Price

Open 0.60 Change Price %
High 0.73 1 Day 0.02 3.51
Low 0.56 1 Week -0.01 -1.67
Close 0.59 1 Month -0.08 -11.94
Volume 424010 1 Year -3.41 -85.25
52 Week High 4.93
52 Week Low 0.50
OPXA Important Levels
Resistance 2 0.75
Resistance 1 0.68
Pivot 0.63
Support 1 0.50
Support 2 0.43
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Opexa Therapeutics, Inc. (NASDAQ: OPXA)

OPXA Technical Analysis 5
As on 23rd Jun 2017 OPXA Share Price closed @ 0.59 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.72 & Strong Sell for SHORT-TERM with Stoploss of 0.63 we also expect STOCK to react on Following IMPORTANT LEVELS.
OPXA Target for June
1st Target up-side 0.66
2nd Target up-side 0.72
3rd Target up-side 0.78
1st Target down-side 0.5
2nd Target down-side 0.44
3rd Target down-side 0.38
OPXA Other Details
Segment EQ
Market Capital 14797129.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.opexatherapeutics.com
OPXA Address
OPXA
2635 Technology Forest Boulevard
The Woodlands, TX 77381
United States
Phone: 281-272-9331
Fax: 281-872-8585
Interactive Technical Analysis Chart Opexa Therapeutics, Inc. ( OPXA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Opexa Therapeutics, Inc.
OPXA Business Profile
Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in developing personalized cellular therapies with the potential to treat illnesses, including multiple sclerosis (MS). These therapies are based on its T-cell technology. The Company�s core product candidate, Tovaxin, is a personalized T-cell therapeutic vaccine licensed from Baylor College of Medicine, which is in clinical development for the treatment of MS. Tcelna is a T-cell immunotherapy in Phase IIb clinical development for the treatment of patients with secondary progressive MS (SPMS).Tcelna is a personalized therapy that is specifically tailored to each patient�s disease profile. The TERMS study was a multi-center, randomized, double blind, placebo-controlled trial in 150 patients with RRMS or high risk Clinically Isolated Syndrome.